Multicentre Trial Of Calcium Channel Blocker Versus Calcium Channel Blocker Plus Cox2 Inhibitor In Preterm Labour
Funder
National Health and Medical Research Council
Funding Amount
$644,130.00
Summary
Preterm birth is a major problem in our society, and has enormous consequences for parents and children. It also has a major impact on scarce financial resources. When women present in preterm labor, current therapies have only limited success in stopping contractions and postponing birth. They have not been shown to reduce the rates of the serious neonatal problems associated with prematurity. This project will be coordinated in Newcastle, N.S.W., and will involve major perinatal centres throug ....Preterm birth is a major problem in our society, and has enormous consequences for parents and children. It also has a major impact on scarce financial resources. When women present in preterm labor, current therapies have only limited success in stopping contractions and postponing birth. They have not been shown to reduce the rates of the serious neonatal problems associated with prematurity. This project will be coordinated in Newcastle, N.S.W., and will involve major perinatal centres throughout Australia, along with overseas centres. It will test a new combination of drugs for their ability to postpone delivery in women presenting with preterm labour. It is postulated that the combination of drugs will be more effective than existing therapies. The drugs used in the trial are Nifedipine and Rofecoxib. Complications of prematurity include neonatal death, cerebral palsy, visual and hearing impairment, and chronic lung disease. These complications are most significant in extremely premature infants - in particular, those under 28 weeks gestation at the time of their delivery. For this reason, the study will focus only on women presenting in labour below 28 weeks. The ability to stop labour is important, but the main aim of any treatment for preterm labour is to reduce the rates of neonatal death and handicap. Babies born to women enrolled in this study will be followed for a period of one year after birth to assess their outcomes. It is our hypothesis that the combination of Rofecoxib and Nifedipine will result in lower rates of death and handicap in babies than Nifedipine alone. In addition, we will examine the rates of side effects in women receiving therapy. Currently used therapies, including intravenous ventolin, have high rates of maternal side effects. Nifedipine and Rofecoxib have both been shown to have low rates of maternal side effects.Read moreRead less
A Study Of The Impact Of Treating Electrographic Seizures In Term Or Near-term Infants With Neonatal Encephalopathy
Funder
National Health and Medical Research Council
Funding Amount
$1,365,184.00
Summary
Seizures in the newborn infant are common and may be harmful to the developing brain. They are not always recognised. This study investigates whether or not treating all seizures detected using a bedside brain activity monitor improves developmental outcome, compared to just treating seizures that doctors recognise.
Perinatal Stress Leads To Neurosteroid Deficits And Adverse Behavioural Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$1,198,042.00
Summary
This grant will examine the effect of psychosocial stress experienced after birth on the production and regulation of steroid hormones in the brain of newborn animals. The work will investigate how stress changes the levels these brain steroids and sensitivity to them and if these effects are remain into adulthood. The studies will then determine if these changes lead to adolescent behaviour disorders. The effectiveness of steroid therapies in treating these disorders will also be determined.
Antibiotic Treatment Of Male Partners To Reduce Recurrence Of Bacterial Vaginosis In Women: A Randomised Double-blind Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$636,674.00
Summary
Bacterial vaginosis (BV) is the most common vaginal infection in women. Healthy bacteria are lost and replaced by bacteria that cause unpleasant discharge and odour. BV puts women at increased risk of sexually transmitted infections, HIV, miscarriage and preterm delivery. Over 50% of women given antibiotics get BV back again. Studies suggest these bacteria are being sexually transmitted. We are conducting a trial of antibiotic treatment of women and their male partners to improve BV cure.
The Treatment Of BOoking Gestational Diabetes Mellitus Study: The TOBOGM Study
Funder
National Health and Medical Research Council
Funding Amount
$2,197,280.00
Summary
Gestational diabetes mellitus (GDM) related pregnancy complications are reduced with treatment from 24-28 weeks pregnant. Many women are diagnosed/treated earlier without evidence of benefit and possible risk of harm. In TOBOGM women under 20 weeks pregnant with mildly raised blood glucose will be allocated by chance to either immediate treatment, or awaiting a repeat diabetes test at 24-28 weeks pregnant to decide treatment. Harmful and beneficial effects on mother and baby will be compared.
Centre For Clinical Research Excellence In Aboriginal Health: Sexually Transmitted And Bloodborne Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$2,553,623.00
Summary
This proposed new CCRE will bring together the leading Australian institution dedicated to clinical research on sexually transmitted and blood borne viral infections, and the peak organisation for Aboriginal Community Controlled Health Services. Working with nominated Aboriginal community controlled health services, the Centre will conduct innovative research that will identify new approaches to diagnosing and managing these infections while at the same time developing improved clinical guidelin ....This proposed new CCRE will bring together the leading Australian institution dedicated to clinical research on sexually transmitted and blood borne viral infections, and the peak organisation for Aboriginal Community Controlled Health Services. Working with nominated Aboriginal community controlled health services, the Centre will conduct innovative research that will identify new approaches to diagnosing and managing these infections while at the same time developing improved clinical guidelines and research capacity within the sector.Read moreRead less
Anti-sporulation Strategies For Clostridium Difficile Infections
Funder
National Health and Medical Research Council
Funding Amount
$651,559.00
Summary
Hospital-acquired infections with the bacterium Clostridium difficile are a major global public health concern with highly virulent isolates emerging overseas in 2002 and in Australia in 2010. These strains have spread through our hospitals and are also found in the community. This project will increase our understanding of how these strains spread and will provide knowledge that is critical for developing improved strategies for preventing these infections.
A Longitudinal Study Of Bacterial Vaginosis And Mycoplasma Genitalium In Young Australian Women.
Funder
National Health and Medical Research Council
Funding Amount
$102,270.00
Summary
The aim of this research project is to measure how many Australian women are infected with either bacterial vaginosis or Mycoplasma genitalium. These infections can be associated with significant reproductive complications for women. Very little is know about how common these infections are or how often they can occur. This study will follow 1400 women over 12 months, asking them to provide vaginal swabs through the post for testing for these infections.
ADVANCING THE EVIDENCE BASE FOR CARE AND POLICY IN PRIORITY HEALTH AREAS
Funder
National Health and Medical Research Council
Funding Amount
$11,195,727.00
Summary
This program will improve health care and policy through clinical trials research and better methods for combining trial evidence. The team will tackle priority health areas to reduce death and serious disability: in particular in cancer, cardiovascular disease, diabetes, obesity and neonatal diseases. The program team includes clinicians, epidemiologists, trialists, biostatisticians, and health economists and collaborative networks of clinical investigators in each disease area.
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.